The incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on $^{18}$F-FDG PET-CT

Authors: Mohamed S El-Sayed, Godfrey N Wechie, Chen Sheng Low, Oludolapo Adesanya, Nikhil Rao and Vincent J Leung

Objectives
Reactive axillary lymph nodes (ALN) may occur post-COVID-19 vaccination. This may be confused with malignant nodal metastases on oncological imaging. We aimed to determine the reactive ALN incidence and duration on $^{18}$F-fluorodeoxyglucose positron emission tomography – computed tomography ($^{18}$F-FDG PET-CT), and its relationship with gender, age and vaccine type.

Methods
A retrospective study was performed. Two-hundred and four eligible patients had $^{18}$F-FDG PET-CT between 01 January 2021 and 31 March 2021, post-vaccination with Pfizer-BioNTech or Oxford-AstraZeneca vaccine. Image analysis was performed on dedicated workstations. SPSS was used for statistical analysis.

Results
Thirty-six per cent of patients had reactive ALN until 10 weeks post-vaccination; reducing in frequency and intensity with time. Women were more likely to have reactive ALN compared with men. The frequency and intensity were higher in patients aged <65 years compared with those aged ≥65 years. However, no difference was found between both vaccine types in our study cohort.

Conclusions
Physicians’ awareness of COVID-19 vaccine-related reactive ALN on $^{18}$F-FDG PET-CT is important to avoid inappropriate upstaging of cancers.

KEYWORDS: COVID-19 vaccine, $^{18}$F-FDG PET-CT, lymphadenopathy

DOI: 10.7861/clinmed.2021-0420

Introduction
The COVID-19 pandemic has rapidly spread around the world causing devastating effects to millions of people. While this situation is still ongoing, the resilience of the global society is constantly being challenged. In response to the pandemic, unprecedented investments have been made in vaccine development.

The UK had the international lead in rolling out the COVID-19 mass vaccination programme on 08 December 2020.1 The Medicines and Healthcare products Regulatory Agency gave regulatory approval for the Pfizer-BioNTech vaccine in the UK on 02 December 2020, followed by the Oxford-AstraZeneca vaccine on 30 December 2020.2,3

Like all vaccines, COVID-19 vaccines carry a potential to cause side effects, of which, the most common being local inflammation at the injection site. Local enlarged lymphadenopathy can also occur, however, this is reported as being uncommon at <1 in 100 administrations.2,3

There is emerging data that describe the effect of COVID-19 vaccine on the $^{18}$F-fluorodeoxyglucose positron emission tomography – computed tomography ($^{18}$F-FDG PET-CT) imaging appearances. This modality uses a glucose analogue to image metabolic activities of various pathologies, predominately tumours, but also inflammation and infection. A number of published case reports illustrate increased $^{18}$F-FDG uptake in ipsilateral axillary lymph nodes (ALN) after administration of COVID-19 vaccines in the deltoid muscle.4–7 However, paucity of data means that the incidence and expected duration of uptake is not well established, particularly with different vaccine types.

The appearance of the reactive ALN may be confused with malignant nodal metastases on oncological imaging. Therefore, establishing accurate data regarding the vaccine effect is of extreme importance to avoid inappropriate management of patients with cancer.

We performed a study documenting the effect of the COVID-19 vaccine on the incidence of reactive axillary lymphadenopathy on $^{18}$F-FDG PET-CT at different time points post-vaccination with two different vaccine types.

Materials and methods
Study sample and data collection
The study was performed at a major tertiary hospital. It was approved by the institutional COVID-19 research committee and
Brown fat activity

Soft tissue infection/

Vaccine date not available

< max

Sarcoidosis or TB with known ALN

Widespread nodal metastases

< max

Reactive ALN contralateral to vaccination site

Excision biopsy of ALN within 6 weeks before the scan

> max

ALN clearance on either side

Brown fat activity

Soft tissue infection/ inflammation in the axillary or shoulder region

Table 1. Detailed exclusion criteria

| Inadequate vaccination information | ALN pathologies | Conditions impairing the interpretation of ALN findings |
|-----------------------------------|-----------------|------------------------------------------------------|
| Vaccine site not available | Known ALN metastases on either side (on histopathology and/or imaging prior to vaccination) | Widespread nodal metastases above the diaphragm |
| Vaccine date not available | Sarcoïdosis or TB with known ALN involvement (on histopathology and/or imaging prior to vaccination) | ALN clearance on either side |
|                                | Reactive ALN contralateral to vaccination site |Brown fat activity |
|                                | Excision biopsy of ALN within 6 weeks before the scan | Soft tissue infection/ inflammation in the axillary or shoulder region |

ALN = axillary lymph nodes; TB = tuberculous.

research and development department. The need for written informed consent was waived due to the retrospective and observational nature of the study.

Eligible subjects were patients who had an $^{18}$F-FDG PET-CT at our institution after receiving their COVID-19 vaccination. PET-CT were performed as part of the routine clinical care with a range of indications falling within the Royal College of Radiologists’ guidelines. Our nuclear medicine department started routinely documenting the details of the vaccination at the beginning of January 2021 to aid clinical interpretation of the PET-CT. Therefore, data were collected from 01 January 2021 until 31 March 2021. Exclusion criteria were inadequate vaccination information, and patients with ALN pathologies or with conditions impairing the interpretation of ALN findings (Table 1).

COVID-19 vaccine

All patients in this study received either the Pfizer-BioNTech or the Oxford-AstraZeneca vaccine. On 30 December 2020, the UK declared a deviation from the recommended vaccination schedule for the Pfizer-BioNTech vaccine, prolonging the interval between doses from 3 to 12 weeks. The same decision was made for the Oxford-AstraZeneca vaccine, prolonging the interval between doses from 3 to 12 weeks. The maximum standardised uptake value (SUV$_{\text{max}}$) and size of ALN (ipsilateral and contralateral to vaccination site) were collected using an Advantage Workstation version 4.6 with 3D volume viewer software 11.3 (GE Healthcare, Chicago, USA). This provides an automatically delineated volume of interest (VOI) using an isocontour threshold method based on SUV. A VOI was drawn over the most avid ipsilateral ALN and over a representative contralateral ALN to obtain SUV$_{\text{max}}$ values. The size of the ALN on both sides were measured on CT and recorded as either non-enlarged if <1 cm or enlarged if >1 cm.

Statistical analysis

Normally distributed continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as numbers and percentages.

Student’s t-test was used for the normally distributed continuous variables. The chi-squared test was used for categorical variables. Statistical significance was defined as p<0.05.

The contralateral ALN SUV$_{\text{max}}$ was used to control for background activity by subtracting it from the ipsilateral ALN SUV$_{\text{max}}$. This gave the difference in SUV$_{\text{max}}$ (dSUV) between ipsilateral and contralateral ALN. One SD of the contralateral ALN mean SUV$_{\text{max}}$ was used as a cut-off for considering dSUV as positive for reactive lymphadenopathy.

Statistical analysis was performed using IBM SPSS, version 26 (IBM, Armonk, USA).

Results

A total of 319 patients had $^{18}$F-FDG PET-CT after receiving their COVID-19 vaccination. After excluding 115 patients who did not meet the study’s eligibility criteria, a total of 204 patients were included in the study (Fig 1). The characteristics of the study population are summarised in supplementary material S2.

Avidity in ipsilateral vs contralateral ALN

The mean SUV$_{\text{max}}$ in the ipsilateral ALN (1.9 g/mL; SD 1.7) was higher than in the contralateral ALN (1.1 g/mL; SD 0.7; p<0.001). Using the latter SD, the cut-off for positive reactive ALN was determined to be dSUV >0.7 g/mL.

Seventy-four out of 204 patients (36%) had avid ipsilateral ALN which was seen up to 10-weeks post-vaccination (Fig 2), however, reducing in frequency and intensity with time. No positive ALN was seen after 10-weeks post-vaccination (Fig 3; Table 2). None of the avid lymph nodes in our study sample was enlarged by size criteria.

Gender

Within 6 weeks of vaccination, the mean dSUV was higher in women (1.3 g/mL; SD 1.8) compared with men (0.9 g/mL; SD 1.7).
PET-CT COVID-19 vaccine-related lymphadenopathy

**Fig 1. Included and excluded patients.** $^{18}$F-FDG PET-CT = $^{18}$F-fluorodeoxyglucose positron emission tomography – computed tomography; ALN = axillary lymph nodes.

This did not achieve statistical significance ($p=0.26$). However, there was a statistically significant higher percentage of women who had positive reactive ALN compared with men ($p=0.04$; Table 3).

**Age**

Within 6 weeks of vaccination, the mean dSUV in patients aged <65 years (1.6 g/mL; SD 2) was higher than in patients aged ≥65 years (0.8 g/mL; SD 1.6; $p=0.021$). Moreover, a higher percentage of patients aged <65 years had positive reactive ALN compared with those aged ≥65 years ($p=0.03$; Table 3). All these differences were statistically significant.

**Vaccine type**

The vaccine type was available for 105/204 (51%) patients: 62/105 (59%) had the Pfizer-BioNTech vaccine and 43/105 (41%) had the Oxford-AstraZeneca vaccine. Within 6 weeks of vaccination, patients who received the Oxford-AstraZeneca vaccine showed higher mean dSUV in the ipsilateral ALN (1.1 g/mL; SD 1.5) than those who received the Pfizer-BioNTech vaccine (0.8 g/mL; SD 1.7; $p=0.43$). Similarly, a higher percentage of the patients who received the Oxford-AstraZeneca vaccine showed positive ALN compared with those who received the Pfizer-BioNTech vaccine ($p=0.08$; Table 3). None of these differences reached statistical significance.

**Discussion**

This study assessed the incidence of $^{18}$F-FDG uptake at various time points following one of two different COVID-19 vaccine types: an mRNA vaccine or an adenoviral vector vaccine. The cohort includes patients at varying times post-vaccination; with several who had vaccination >10 weeks prior to their PET-CT. The data show that reactive $^{18}$F-FDG avidity is seen in the ALN ipsilateral to the vaccinated arm in the majority of patients within the first 2 weeks post-vaccination, with a gradual reduction in the intensity of avidity and number of patients showing this effect over a 10-week period. We strictly excluded patients with pathology that might involve the ALN to avoid false positive cases.

Several case reports have already described reactive $^{18}$F-FDG uptake in ALN ipsilateral to the vaccinated arm secondary to local inflammation and immune response.4–7 This has been a well-recognised process with other vaccinations prior to the COVID-19 pandemic.11–13 However, given the nature of the mass vaccination in COVID-19, this feature is now seen routinely in clinical practice and may impair the clinical interpretation of $^{18}$F-FDG PET-CT. Prior to the COVID-19 pandemic, the published evidence described vaccine-related $^{18}$F-FDG uptake in ipsilateral ALN up to 2 weeks post-vaccination for influenza.11–13 However, the evolving evidence demonstrates that the duration is longer with COVID-19 vaccine. McIntosh et al observed $^{18}$F-FDG uptake in ipsilateral ALN 4–6 weeks post-vaccination.7 Our study shows that avidity in the ipsilateral ALN can be seen up to 10 weeks post-vaccination.

None of the patients in our study population had size enlarged ALN >1 cm. This is compatible with the current available data listing palpable lymphadenopathy as an uncommon side effect of the COVID-19 vaccine.2,3 Therefore, we suggest regarding enlarged local lymph nodes as suspicious until proven otherwise.

---

**Fig 2. Typical appearance of reactive axillary lymph nodes post-COVID-19 vaccination in one of the study patients.** Straight arrow = injection site inflammation in left deltoid muscle (not necessarily seen in all cases); curved arrow = reactive ipsilateral axillary lymph nodes; CT = computed tomography; PET = positron emission tomography.
Fig 3. Relation between axillary lymph nodes dSUV and post-vaccination duration (above the 0.7 line indicates avidity).

These could be investigated further with follow-up imaging or ultrasound-guided biopsy if this would impact on patient management.

Gee et al reported that COVID-19 vaccine side effects occurred more in women compared with men (78.7% vs 20.1%, remainder of unknown gender), and in people aged <65 years compared with those aged ≥65 years (90.4% vs 6.2%, remainder of unknown age). Our data are in line with this as it shows that avid ALN occurred with more frequency and intensity in those two groups of patients. This could be due to sex hormone mediation of immune response, as Potluri et al showed higher immune responses to influenza vaccination in women due to oestradiol. The beneficial effect of the raised oestradiol on immune response in women was reduced with age in that study.

Each of the Pfizer-BioNTech and the Oxford-AstraZeneca vaccines use different technology. The Pfizer-BioNTech vaccine uses an mRNA platform whereas the Oxford-AstraZeneca vaccine uses an adenovirus vector. Despite this difference, our data did not show a significant difference in vaccine-related 18F-FDG avidity between both vaccine types.

18F-FDG PET-CT appearances after COVID-19 vaccination are important to recognise to avoid inappropriate upstaging of cancer cases. This also has to be taken into consideration when these cases are presented at the various multidisciplinary team meetings (MDMs).

Moreover, there are reports in the literature describing post-COVID-19 vaccine reactive ALN uptake in patients having PET-CT with non-FDG tracers; including 68Ga-DOTATATE, 18F-fluciclovine and 11C-choline. These are mainly case reports and, in the case of 11C-choline, a small study of 13 patients. Awareness of this is also important and further research is required to establish the incidence and duration of this reactive uptake in large patient cohorts.

Given the importance of information obtained from imaging, we recommend that both the patients and vaccine clinics are educated about the importance of avoiding the vaccine in the arm ipsilateral to the tumour drainage site. Administration of the vaccine to the vastus lateralis of the thigh is an alternative route within the Public Health England and Centers for Disease Control and Prevention guidelines, although drainage into the inguinal and pelvic nodal groups could potentially cause similar reactive avidity.

Another option is to schedule 18F-FDG PET-CT with a 6 week delay after vaccination, although this would depend on the clinical urgency of the test. Our data suggest that, in patients who had vaccination more than 6 weeks before PET-CT, up to 14.5% only would have reactive avidity in the ALN ipsilateral to the vaccination site.

The majority of the patients in our study had their scan after the 1st vaccine dose. Perhaps, this is because the UK has recommended a 12-week gap between both vaccination doses.

Table 2. Total patients with avid ipsilateral axillary lymph nodes post-vaccination

| Weeks post-vaccination | Total number of patients | Patients with avid ipsilateral ALN | Number | Proportion of specific timepoint group | Proportion of the entire study cohort |
|------------------------|-------------------------|-----------------------------------|--------|----------------------------------------|---------------------------------------|
| <2                     | 56                      | 35                                | 62.5%  | 17%                                   |
| 2–4                    | 43                      | 18                                | 42%    | 9%                                    |
| 4–6                    | 50                      | 13                                | 26%    | 6%                                    |
| 6–8                    | 34                      | 5                                 | 15%    | 2.5%                                  |
| 8–10                   | 16                      | 3                                 | 19%    | 1.5%                                  |
| >10                    | 5                       | 0                                 | 0%     | 0%                                    |
| Total                  | 204                     | 74                                | –      | 36%                                   |

ALN = axillary lymph nodes.
Therefore, a mass population receiving the 2nd vaccination dose was not seen in the study period. Further studies would be required to establish the duration of avidity after the 2nd dose as the side effects are reported to be more intense for some vaccine types. Dedicated studies based on the vaccine type and duration between the two doses would be needed as there may be a difference based on these factors.

The main limitation of our study was the retrospective nature and absence of data on confounding factors that may affect 18F-FDG uptake; for example, data on recent chemotherapy was not collected. As the majority of patients in the cohort had a known malignancy, there may be a significant proportion who have had recent chemotherapy that could reduce the immune response. However, in our standard clinical practice, 18F-FDG PET-CT is scheduled with a gap of at least 14 days since the latest chemotherapy to minimise such effect. Furthermore, the cohort is representative of patients having 18F-FDG PET-CT under the UK guidelines only.

Another limitation of the study was that patients were vaccinated in stages according to the UK JCVI priority groups. With exception to health and social care workers and those living in care homes, the initial prioritisation was based on older age groups. However, the study still included a wide age range, as the fourth priority group included ‘clinical extremely vulnerable patients’ regardless of the age; this group encompasses many patients referred for PET-CT, such as patients with cancer on chemotherapy.

Finally, the COVID-19 vaccine type was available in only 51% of the study subjects, which has led to a relatively small patient cohort with known vaccine type. Therefore, despite no significant difference found in our study between both vaccine types in the vaccine-related 18F-FDG avidity, further research is needed to support this finding.

**Conclusion**

This study shows that COVID-19 vaccines can cause reactive avidity in the ALN ipsilateral to the vaccination site on 18F-FDG PET-CT within the first 6 weeks post-vaccination; this may persist for up to 10 weeks. Women and those aged <65 years are more likely to have this effect. This should be accounted for not only by the PET reporting radiologists but also by all the clinical teams reviewing these scans at the various MDMs. This is crucial to avoid inappropriate upstaging of cancer cases.

### Table 3. Subgroup analysis of patients with avid ipsilateral axillary lymph nodes post-vaccination

| Weeks post-vaccination | Male | Female | P value |
|------------------------|------|--------|---------|
| <6                     | 27/78 (35%) | 39/76 (51%) | 0.04     |
| ≥6                     | 3/20 (15%)  | 5/30 (17%)   | 0.88     |
| Aged <65 years         | 29/53 (55%) | 37/101 (37%) | 0.03     |
| ≥6                     | 5/13 (38.5%) | 3/37 (8%)    | 0.01     |
| Pfizer-BioNTech        | 14/42 (33%) | 19/36 (53%) | 0.08     |
| ≥6                     | 4/20 (20%)  | 2/7 (29%)    | 0.64     |

**Summary**

**What is known about this topic?**
COVID-19 vaccines may cause reactive lymphadenopathy on 18F-FDG PET-CT.

**What question did this study address?**
What is the incidence and duration of COVID-19 vaccine-related reactive lymphadenopathy on 18F-FDG PET-CT, and is there any difference according to gender, age or vaccine type?

**What did this study find?**
Reactive 18F-FDG uptake was seen in axillary lymph nodes of 36% of vaccinated patients and up to 10 weeks post-vaccination.

Women and those aged <65 years are more likely to be affected.

There was no significant difference between the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in causing this finding. None of the reactive lymph nodes were enlarged.

**What is the implication for practice now?**
Recognition of this finding by all physicians is important to avoid incorrect upstaging of cancers. Particularly as the vaccination history may not be available to the PET reporter.

**Supplementary material**

Additional supplementary material may be found in the online version of this article at www.rcpjournals.org/clinmedicine:
S1 – COVID-19 vaccine priority groups based on UK Joint Committee on Vaccination and Immunisation recommendations.
S2 – Baseline characteristics of the patients included in the study.

**Acknowledgements**

We would like to acknowledge the support of the University Hospitals Coventry and Warwickshire COVID-19 Vaccine Action Centre.

**References**

1. Baraniuk C. Covid-19: How the UK vaccine rollout delivered success, so far. BMJ 2021;372:n421.
2. Medicines and Healthcare products Regulatory Agency. Regulatory approval of Pfizer/BioNTech vaccine for COVID-19. REG 174 Information for UK healthcare professionals. MHRA, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/
Incidence and intensity of F-18 FDG uptake after vaccination with COVID-19 vaccine. Lancet 2021;397:e9.
10 Department of Health and Social Care. Optimising the COVID-19 vaccination programme for maximum short-term impact. DHSC, 2021. www.gov.uk/government/publications/prioritising-the-healthcare-workers_26-February_2021_v3.4.pdf [Accessed 24 May 2021].
11 Burger IA, Husmann L, Hany TF, Schmid DT, Schaefer NG. Incidence and intensity of F-18 FDG uptake after vaccination with H1N1 vaccine. Clin Nucl Med 2011;36:848–53.
12 Panagiotidis E, Exarhos D, Housianakou I, Bourmanos A, Datseris. FDG uptake in axillary lymph nodes after vaccination against pandemic (H1N1). Eur Radiol 2010;20:1251–3.
13 Shirone N, Shinkai T, Yamane T et al. Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination. Ann Nucl Med 2012;26:248–52.
14 Gee J, Marquez P, Su J et al. First month of COVID-19 vaccine safety monitoring - United States, December 14, 2020 – January 13, 2021. MMWR Morb Mortal Wkly Rep 2021;70:283–8.
15 Potouri T, Fink AL, Sylvia KE et al. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines 2019;4:29. Erratum in: NPJ Vaccines 2019;4:35.
16 Brophy J, Henkle G, Rohren EM. DOTATATE uptake in an axillary lymph node after COVID-19 vaccination. Clin Nucl Med 2021 [Epub ahead of print].
17 Shah HJ, Halpern JJ, Watane GV, Hyun H. COVID lessons continue: postvaccination somatostatin receptor-positive axillary nodes on DOTATATE imaging. Clin Nucl Med 2021 [Epub ahead of print].
18 Wang FC, Martinova I, Masrani A, Ravizzi GC. 18F-fluorodioxime-avid reactive axillary lymph nodes after COVID-19 vaccination. Clin Nucl Med 2021;46:e97–9.
19 Schroeder DG, Jang S, Johnson DR et al. Frequency and characteristics of nodal and deltoid FDG and 11C-choline uptake on PET imaging performed after COVID-19 vaccination. AJR Am J Roentgenol 2021;217:975–83.
20 Public Health England. COVID-19 vaccination programme Information for healthcare practitioners. PHE, 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/965177/COVID-19_vaccination_programme_guidance_for_healthcare_workers_26_February_2021_v3.4.pdf [Accessed 24 May 2021].
21 Centers for Disease Control and Prevention. Pfizer-BioNTech COVID-19 Vaccine Standing Orders for Administering Vaccine to Persons 16 Years of Age and Older. CDC, 2021. www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/standing-orders.pdf [Accessed 24 May 2021].
22 Shimabukuro T. COVID-19 vaccine safety update: Advisory Committee on Immunization Practices (ACIP). CDC, 2021. www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/28-03-01/05-covid-Shimabukuro.pdf [Accessed 24 May 2021].

Address for correspondence: Dr Mohamed S El-Sayed, Department of Nuclear Medicine, University Hospital, Clifford Bridge Road, Coventry CV2 2DX, UK.
Email: mohamed.el-sayed@nhs.net
Twitter: @Doc_M_EL_Sayed